^
    Back
    Association details:
    Biomarker:IDO1 expression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2023
    Title:

    4341 / 16 - Indoleamine 2,3-dioxygenase 1 is highly expressed in tertiary lymphoid structures and associated with improved outcome in patients with advanced non-small cell lung cancer treated with anti-PD1/PDL1 inhibitors

    Published date:
    03/15/2023
    Excerpt:
    The aim of our study was to investigate the role of IDO1 expression in the outcome of NSCLC patients treated with immunotherapy….IDO1 expression by tumor cells in NSCLC is associated with improved outcome in patients with NSCLC, independently of PDL1 expression score.